Literature DB >> 17485354

Roles of AKT signal in breast cancer.

Wen Liu1, Juhi Bagaitkar, Kounosuke Watabe.   

Abstract

The PI3K/Akt pathway plays a central role in a variety of cellular processes including cell growth, proliferation, motility and survival in both normal and tumor cells. The PI3K/Akt pathway is also instrumental in epithelial mesenchymal transitions and in angiogenesis during tumorigenesis. Many of the transforming events in breast cancer are a result of enhanced signaling of the PI3K/Akt pathway. Akt therefore is considered to be a rational target for cancer therapies and inhibitors of the PI3K/Akt pathway have been identified. In this review, we discuss the recent information about the functional roles of PI3K/Akt pathway in tumorigenesis and progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485354     DOI: 10.2741/2367

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  37 in total

1.  The time course of Akt and ERK activation on XIAP expression in HEK 293 cell line.

Authors:  Mousa Abkhezr; Ali Reza Keramati; Seyed Nasser Ostad; Jamshid Davoodi; Mohammad H Ghahremani
Journal:  Mol Biol Rep       Date:  2009-08-02       Impact factor: 2.316

2.  Regulation of IKKε Expression by Akt2 Isoform.

Authors:  Soumya Krishnamurthy; Alakananda Basu
Journal:  Genes Cancer       Date:  2011-11

3.  Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.

Authors:  Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

4.  Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.

Authors:  Michael F Ochs; Lori Rink; Chi Tarn; Sarah Mburu; Takahiro Taguchi; Burton Eisenberg; Andrew K Godwin
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

5.  Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Authors:  Carmen Blanco-Aparicio; Marta Cañamero; Yolanda Cecilia; Belén Pequeño; Oliver Renner; Irene Ferrer; Amancio Carnero
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

6.  Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Authors:  Maria Laura Polo; Maria Victoria Arnoni; Marina Riggio; Victoria Wargon; Claudia Lanari; Virginia Novaro
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

7.  The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane.

Authors:  N Berndt; H Yang; B Trinczek; S Betzi; Z Zhang; B Wu; N J Lawrence; M Pellecchia; E Schönbrunn; J Q Cheng; S M Sebti
Journal:  Cell Death Differ       Date:  2010-05-21       Impact factor: 15.828

8.  Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis.

Authors:  Norbert Berndt; Ronil Patel; Hua Yang; Maria E Balasis; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

9.  Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.

Authors:  Lisa M Arendt; Lindsay C Evans; Debra E Rugowski; Maria Jose Garcia-Barchino; Hallgeir Rui; Linda A Schuler
Journal:  J Endocrinol       Date:  2009-07-27       Impact factor: 4.286

10.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.